Ustekinumab in the treatment of severe rupioid psoriasis: A case report

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 19, Issue 2, 2010, Pages 23-27

  Nečas, Miroslav ^a   Vašků, Vladimir ^a  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Biologicals; Psoriasis; Ustekinumab

Indexed keywords

CITALOPRAM; FLUINDOSTATIN; GLYCOSYLATED HEMOGLOBIN; IBUPROFEN; LEFLUNOMIDE; LOSARTAN; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; USTEKINUMAB;

ADULT; ALCOHOLISM; ARTHRALGIA; ARTHRITIS; ARTICLE; CASE REPORT; CONVALESCENCE; DEPRESSION; DISEASE SEVERITY; DRUG TOLERANCE; FAMILY HISTORY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOLIPEMIA; LEUKOCYTOSIS; MALE; METABOLIC SYNDROME X; PHOTOTHERAPY; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SACROILIITIS; SMOKING; SPONDYLOARTHROPATHY; SYSTEMIC THERAPY; THORAX RADIOGRAPHY; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TUBERCULIN TEST;

ANTIBODIES, MONOCLONAL; HUMANS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77955817649     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Griffiths CEM, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, Doria A. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol. 2006;24(1 Suppl. 40):72-8.
2. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicals. J Am Acad Dermatol. 2008;58(5):826-50.
3. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists guidelines for use of biological interventions in psoriasis. Br J Dermatol. 2005;153(3):486-7.
4. Vašků V, Bienertová Vašků J, Pávková Goldbergová M, Vašků A. Three retinoid X receptor gene polymorphism in plaque psoriasis and psoriasis guttata. Dermatology. 2007;214:118-24.
5. Vašků V, Vašků Bienertová J, Slonková V, Kaňkové K, Vašků A. Matrix metalloproteinase-2 promoter variability in psoriasis. Arch Dermatol Res. 2009;301:467-73
6. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologies. J Am Acad Dermatol. 2008;58(5):851-4.
7. Boker A, Kimball AB, Rolz-Cruz G. Biologicals in the treatment of psoriasis. Curr Opin Investig Drugs. 2007;8(11):939-6.
8. Barlett BL, Tyring SK. Ustekinumab for chronic plaque psoriasis. Lancet. 2008;371(9625):1639-40.
9. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol. 2007;57(6):1059-68.
10. Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U. Modulation of CLA, IL-12R, CD40L, and IL-2Pα expression and inhibition of IL-12 and IL-23 induced cytokine secretion by CNTO 1275. Cell Immunol. 2007;247(1):1-11.
11. Leonardi CL, Kimball AB, Papp KA, Yielding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-74.
12. Steinman LA. A brief history of Th 17, the first major revision in the Th1/Th2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13(2):139-45.
13. Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: a new therapeutic target in inflammatory dermatoses. J Dermatolog Treat. 2008;19(6):318-26.
14. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-84.
15. Weber J, Keam SJ. Ustekinumab. BioDrugs. 2009;23(1):53-61.
16. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580-592.
17. Electronic Medicines Compendium [Internet]. SPC Stelara 45 mg solution for injection. Summary of Product Characteristics [updated 26 Jan 2009, cited 27 Jan 2009]. Available from: http://emc.medicines.org.uk/medicine/21425/SPC/ Stelara.